eFFECTOR Therapeutics, Inc. (EFTR)

2.1600 -0.0400 (-1.82%) 收市：04:00PM EDT

eFFECTOR Therapeutics, Inc.

142 North Cedros Avenue
Suite B
Solana Beach, CA 92075
United States
858 925 8215
https://effector.com

版塊: Healthcare
行業: Biotechnology
全職員工: 14

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Stephen T. Worland Ph.D.	CEO, President & Director	873.96k	無	1958
Mr. Michael Byrnes M.B.A.	Chief Financial Officer	654.82k	無	1977
Dr. Douglas Warner M.D.	Chief Medical Officer	660.16k	無	1972
Dr. Davide Ruggero Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	無	無	無
Dr. Kevan M. Shokat Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

公司管治

截至 無 止，eFFECTOR Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。